{"id":26045,"date":"2025-06-30T02:48:11","date_gmt":"2025-06-30T02:48:11","guid":{"rendered":"https:\/\/www.europesays.com\/us\/26045\/"},"modified":"2025-06-30T02:48:11","modified_gmt":"2025-06-30T02:48:11","slug":"urgent-ozempic-warning-every-aussie-needs-to-hear-as-concerning-trend-emerges-follow-the-instructions","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/26045\/","title":{"rendered":"Urgent Ozempic warning every Aussie needs to hear as concerning trend emerges: ‘Follow the instructions’"},"content":{"rendered":"

By SARAH BROOKES FOR DAILY MAIL AUSTRALIA<\/a> <\/p>\n

Published: 20:48 EDT, 29 June 2025 | Updated: 20:57 EDT, 29 June 2025 <\/p>\n

Aussies have been issued a warning about Ozempic as the number of patients being hospitalised for mistakenly overdosing on weight loss<\/a> medications soars in one state.<\/p>\n

The NSW<\/a> Poisons Information Centre received 332 distressed calls in 2024 from patients using semaglutide – a type 2 diabetes injection that trades under brand names such as Ozempic and Wegovy.<\/p>\n

Calls seeking advice on poisonings from semaglutide spiked by 1,176 per cent in four years, the Daily Telegraph<\/a>\u00a0reported<\/p>\n

Hospital management was required in 21 per cent of cases.\u00a0In 2020, just 26 residents called the centre for help.<\/p>\n

NSW Poisons Information Centre senior specialist Genevieve Adamo said semaglutide was a GLP-1 agonist used to treat type 2 diabetes<\/a>, but more recently had gained popularity among the public for off-label use for weight loss.\u00a0<\/p>\n

‘To prevent accidental medication errors from GLP-1 agonists, NSW PIC advises the community to always write down or mark off the dose on a chart and always follow the instructions on the label,’ she said.<\/p>\n

‘Ensure your doctor, diabetes educator, nurse or pharmacist has given you clear instructions on how to use your medicine, particularly on how to load a dose and inject correctly.’<\/p>\n

Common symptoms of semaglutide overdose include persistent nausea, vomiting, and diarrhoea, as well as intense headaches and hypoglycaemia (blood sugar).<\/p>\n

\"In <\/p>\n

In a disturbing trend more than one in five overdose patients required hospital treatment (stock image)<\/p>\n

More serious side effects that require immediate medical attention include acute pancreatitis and gallstones.<\/p>\n

Last year, the PBS recorded more than 2.5 million prescriptions across Australia, a massive jump from 45,705 scripts in 2020 when the drug was first listed on the PBS.\u00a0<\/p>\n

The Therapeutic Goods Administration (TGA) has not approved Ozempic for weight loss, while Mounjaro and Wegovy can be prescribed for fat-loss purposes in ‘very limited’ cases.<\/p>\n

The TGA announced this month that Novo Nordisk, the pharmaceutical company that supplied Ozempic, had doubled the dose contained in the pre-filled pens from 1.5mL to 3mL.\u00a0<\/p>\n

The new 3 mL pen landed on chemist shelves this month\u00a0and injects a slightly larger volume per dose.<\/p>\n

The TGA urged doctors to warn Ozempic users to ‘be careful’ and check the dose before administering it.\u00a0\u00a0<\/p>\n

Earlier this month, official data revealed more than 100 deaths in the United Kingdom had now been linked to blockbuster weight loss jabs.\u00a0<\/p>\n

Two of the victims were people in their 20s, according to a MailOnline analysis of logs kept by the medicines safety watchdog.<\/p>\n

\"There <\/p>\n

There has been a large increase in the number of people overdosing on weight loss drugs (stock image)<\/p>\n

The findings come as the Medicines and Healthcare Products Regulatory Agency confirmed at least ten people in the UK who used the injections have died from pancreatitis, a life-threatening inflammation of the pancreas.<\/p>\n

The country’s Royal Osteoporosis Society has also linked weight loss drugs\u00a0to osteoporosis and increased risk of bone fractures.<\/p>\n

Share or comment on this article:
\n Urgent Ozempic warning every Aussie needs to hear as concerning trend emerges: ‘Follow the instructions’<\/p>\n","protected":false},"excerpt":{"rendered":"By SARAH BROOKES FOR DAILY MAIL AUSTRALIA Published: 20:48 EDT, 29 June 2025 | Updated: 20:57 EDT, 29…\n","protected":false},"author":3,"featured_media":26046,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[4740,211,210,1060,50,427,67,132,68],"class_list":{"0":"post-26045","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-australia","9":"tag-dailymail","10":"tag-health","11":"tag-medication","12":"tag-news","13":"tag-ozempic","14":"tag-united-states","15":"tag-unitedstates","16":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/114770038382920939","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/26045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=26045"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/26045\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/26046"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=26045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=26045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=26045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}